A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who stop traditional diet and exercise programs.
Findings released in a prominent health publication shows that while obese people frequently drop a large proportion of their body weight while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these treatments need to be informed of the potential of fast rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment weight in about one and a half years.
Comparing Treatments
The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of the injectable medications with conventional dieting.
Researchers point out that individuals who lose weight through diet and exercise usually see a more gradual creep back—around 0.1 kg a month—post-intervention.
Explaining the Fast Rebound
Doctors believe the mode of action of the drugs accounts for the amplified weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines advise the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals argue that, given the likelihood of relapse, the therapy is often ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the findings "underscore the chronic nature of obesity," similar to managing conditions like high blood pressure.
Patient Accounts
Users who have discontinued the medication describe a intense resurgence of hunger.
"It felt as if a switch that goes on and I was suddenly extremely hungry," said a patient.
The struggle is worsened if users have not established sustainable lifestyle or habit modifications during treatment.
Significant Adoption
Figures show that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is more common among females compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and maintained weight loss likely depends on combined lifestyle management.
